Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Signorelli · SciRah

Researcher profile · Semantic Scholar

D. Signorelli

Share profile

D. Signorelli — researcher profile on SciRah

h-index: 35
Works: 170
Citations: 3,993

Most-cited papers

Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
F. Petrelli, D. Signorelli, M. Ghidini, A. Ghidini +11 more
2020Cancers275 citations Open access
Semantic Scholar
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
G. Viscardi, A. Tralongo, Francesco Massari, M. Lambertini +24 more
2022European Journal of Cancer152 citations
Semantic Scholar
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
A. Cortellini, M. di Maio, O. Nigro, A. Leonetti +57 more
2021Journal for ImmunoTherapy of Cancer151 citations Open access
Semantic Scholar
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
A. Cortellini, M. Tiseo, G. Banna, F. Cappuzzo +66 more
2020Cancer Immunology and Immunotherapy94 citations Open access
Semantic Scholar
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
A. Cortellini, B. Ricciuti, M. Tiseo, E. Bria +46 more
2020Journal for ImmunoTherapy of Cancer92 citations Open access
Semantic Scholar
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
A. Cortellini, A. Friedlaender, G. Banna, G. Porzio +67 more
2020Clinical Lung Cancer79 citations Open access
Semantic Scholar
Circulating microRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective study
M. Boeri, M. Milione, C. Proto, D. Signorelli +10 more
2019Clinical Cancer Research77 citations Open access
Semantic Scholar
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
G. Banna, A. Cortellini, D. Cortinovis, M. Tiseo +42 more
2021ESMO Open61 citations Open access
Semantic Scholar
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
G. Galli, A. De Toma, F. Pagani, G. Randon +10 more
2019Lung Cancer60 citations Open access
Semantic Scholar
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
G. Banna, D. Signorelli, G. Metro, D. Galetta +7 more
2020Translational Lung Cancer Research56 citations Open access
Semantic Scholar
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
M. Riudavets, E. Auclin, M. Mosteiro, N. Dempsey +34 more
2022European Journal of Cancer55 citations Open access
Semantic Scholar
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
A. Prelaj, A. Bottiglieri, C. Proto, Giuseppe Lo Russo +18 more
2021European Journal of Cancer53 citations
Semantic Scholar
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
D. Signorelli, P. Giannatempo, G. Grazia, M. Aiello +9 more
2019BioMed Research International49 citations Open access
Semantic Scholar
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
A. Cortellini, A. De Giglio, K. Cannita, D. Cortinovis +47 more
2021Thoracic Cancer48 citations Open access
Semantic Scholar
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
N. Babacan, I. B. Piña, D. Signorelli, A. Prelaj +2 more
2020Clinical Lung Cancer46 citations Open access
Semantic Scholar
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.
G. Metro, A. Addeo, D. Signorelli, A. Gili +18 more
2019Journal of Thoracic Disease43 citations Open access
Semantic Scholar
Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis
F. Petrelli, A. Iaculli, D. Signorelli, A. Ghidini +6 more
2020Journal of Clinical Medicine39 citations Open access
Semantic Scholar
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis.
F. Petrelli, R. Ferrara, D. Signorelli, A. Ghidini +7 more
2021Immunotherapy37 citations
Semantic Scholar
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab
A. Friedlaender, G. Metro, D. Signorelli, A. Gili +18 more
2020Acta oncologica36 citations Open access
Semantic Scholar
STYLE (NCT03449173) a phase II Trial of Sunitinib in patients with type B3 Thymoma or Thymic Carcinoma in second and further lines.
C. Proto, S. Manglaviti, G. L. Russo, M. Musca +34 more
2023Journal of Thoracic Oncology34 citations Open access
Semantic Scholar
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
R. Lobefaro, G. Viscardi, R. Di Liello, G. Massa +17 more
2020Lung Cancer33 citations
Semantic Scholar
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
C. Vernieri, D. Signorelli, G. Galli, M. Ganzinelli +19 more
2019Clinical Lung Cancer33 citations
Semantic Scholar
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.
R. Ferrara, L. Mezquita, M. Texier, J. Lahmar +25 more
2020JCO Precision Oncology32 citations Open access
Semantic Scholar
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
A. Prelaj, E. Galli, V. Mišković, Mattia Pesenti +32 more
2023Frontiers in Oncology31 citations Open access
Semantic Scholar
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
A. Cortellini, K. Cannita, M. Tiseo, D. Cortinovis +48 more
2021European Journal of Cancer31 citations Open access
Semantic Scholar
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
S. Buti, M. Bersanelli, F. Perrone, S. Bracarda +57 more
2021European Journal of Cancer31 citations Open access
Semantic Scholar
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
G. Mountzios, A. De Toma, P. Economopoulou, A. Friedlaender +19 more
2020Clinical Lung Cancer30 citations
Semantic Scholar
First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
G. Scarfone, M. Fumagalli, M. Imbimbo, T. Ceruti +10 more
2021Journal of Thoracic Oncology29 citations Open access
Semantic Scholar
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases
M. Laganà, C. Gurizzan, E. Roca, D. Cortinovis +20 more
2020Frontiers in Oncology27 citations Open access
Semantic Scholar
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
M. Bersanelli, S. Buti, D. Giannarelli, A. Leonetti +48 more
2020Lung Cancer26 citations Open access
Semantic Scholar
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
M. Bersanelli, D. Giannarelli, U. de Giorgi, S. Pignata +69 more
2020Therapeutic Advances in Medical Oncology24 citations Open access
Semantic Scholar
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%
G. Metro, G. Banna, D. Signorelli, A. Gili +19 more
2020Journal of immunotherapy24 citations
Semantic Scholar
Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
E. Pizzutilo, Martino Pedrani, A. Amatu, L. Ruggieri +7 more
2021Cancers23 citations Open access
Semantic Scholar
A systematic review and meta-analysis on the Optimal Treatment duration of cHEckpoint inhibitoRS in solid tumors: the OTHERS study.
G. Bogani, M. Cinquini, D. Signorelli, E. Pizzutilo +15 more
2023Critical reviews in oncology/hematology22 citations Open access
Semantic Scholar
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
A. Servetto, D. Esposito, R. Ferrara, D. Signorelli +6 more
2022Biochimica et biophysica acta. Reviews on cancer22 citations
Semantic Scholar
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
E. Pizzutilo, R. Romanò, L. Roazzi, A. Agostara +7 more
2023Cancer Research18 citations Open access
Semantic Scholar
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
D. Signorelli, Patrizia Ghidotti, C. Proto, M. Brambilla +18 more
2022Frontiers in Immunology17 citations Open access
Semantic Scholar
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
S. Manglaviti, M. Brambilla, D. Signorelli, R. Ferrara +21 more
2021Clinical Lung Cancer15 citations
Semantic Scholar
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis
G. Metro, A. Gili, D. Signorelli, A. De Toma +11 more
2021Clinical and Translational Oncology14 citations
Semantic Scholar
LKB1 down-modulation by miR-17 identifies NSCLC patients with worse prognosis eligible for energy-stress based treatments.
Cristina Borzi, M. Ganzinelli, E. Caiola, M. Colombo +14 more
2021Journal of Thoracic Oncology13 citations Open access
Semantic Scholar
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
G. Metro, D. Signorelli, E. Pizzutilo, L. Giannetta +7 more
2021Human Vaccines & Immunotherapeutics11 citations Open access
Semantic Scholar
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
G. Galli, P. Corsetto, C. Proto, Giuseppe Lo Russo +21 more
2022Clinical Lung Cancer10 citations Open access
Semantic Scholar
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
G. L. Russo, F. Sgambelluri, A. Prelaj, F. Galli +25 more
2022ESMO Open10 citations Open access
Semantic Scholar
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
A. Prelaj, C. Proto, Giuseppe Lo Russo, D. Signorelli +13 more
2020Translational Lung Cancer Research10 citations Open access
Semantic Scholar
Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
Cristina Borzi, G. Galli, M. Ganzinelli, D. Signorelli +4 more
2020Pharmaceuticals10 citations Open access
Semantic Scholar
Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer
G. Galli, C. Proto, M. Cossa, B. Valeri +6 more
2019Tumori10 citations Open access
Semantic Scholar
1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)
R. Ferrara, F. Facchinetti, G. Calareso, I. Kasraoui +16 more
20209 citations Open access
Semantic Scholar
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy.
G. Galli, C. Proto, D. Signorelli, M. Imbimbo +8 more
2019Future Oncology8 citations Open access
Semantic Scholar
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
A. Prelaj, M. Ganzinelli, L. Provenzano, L. Mazzeo +62 more
2023Clinical Lung Cancer7 citations Open access
Semantic Scholar
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
M. Riudavets, É. Auclin, M. Mosteiro, N. Dempsey +35 more
2023Clinical Lung Cancer7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Garassino×29
Invite
M. Garassino — researcher profile on SciRah
A. De Toma×28
Invite
A. De Toma — researcher profile on SciRah
C. Proto×21
Invite
C. Proto — researcher profile on SciRah
G. Galli×17
Invite
G. Galli — researcher profile on SciRah

×16

Invite

A. Prelaj — researcher profile on SciRah

Giuseppe Lo Russo×15

Invite

Giuseppe Lo Russo — researcher profile on SciRah

Invite

R. Ferrara — researcher profile on SciRah

Invite

A. Addeo — researcher profile on SciRah

Invite

G. Metro — researcher profile on SciRah

A. Friedlaender×14

Invite

A. Friedlaender — researcher profile on SciRah

M. Ganzinelli×14

Invite

M. Ganzinelli — researcher profile on SciRah

Invite

G. Banna — researcher profile on SciRah